News | November 15, 2022
Orchid Pharma reports positive EBIDTA in Q2
The company is focussed on increasing the capacity utilizations while controlling costs
The company is focussed on increasing the capacity utilizations while controlling costs
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
The Group will continue to make proactive investments of its management resources in the life science business
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated
